Journal: American Journal of Translational Research

Article Title: Combination of cetuximab with met inhibitor in control of cetuximab-resistant oral squamous cell carcinoma

doi:

Figure Lengend Snippet: HGF induction of OSCC resistance to cetuximab. A. Western blot. HSC-2 and HSC-3 cells were subjected to protein extraction and showed high protein expression levels of EGFR and MET by western blot. B. The MTT assay. HSC-2 and HSC-3 cells were treated with different doses of cetuximab (0-5 µg/mL) and HGF (20 ng/mL) for 72 h, and the cell proliferation levels were shown by the MTT assay. C. Western blot. HSC-2 and HSC-3 cells were pretreated with control, HGF (20 ng/mL), cetuximab (1 µg/mL), or their combination. D. The MTT assay. HSC-2 cells treated with HGF (20 ng/mL) and the HGF neutralizing antibody or cetuximab (1 µg/mL) for 72 h showed different proliferation abilities by the MTT assay. *P < 0.05.

Article Snippet: In brief, 2 × 10 3 tumor cells/well were seeded into 96-well plates and grown for 24 h and then treated with various concentrations of cetuximab (Merck, Germany), PHA-665752 (Selleck Chemicals, TX, USA), HGF (R&D Systems, Minneapolis, MN, USA), and a goat anti-human HGF neutralizing antibody, normal goat IgG (R&D Systems) for 72 h. At the end of each experiment, 50 μL of MTT solution (2 mg/mL; Sigma Chemicals, St. Louis, MO, USA) was added to each well of the cell culture plate, and the cells were incubated for an additional 2 h. The culture medium was replaced with 100 μL of dimethyl sulfoxide.

Techniques: Western Blot, Protein Extraction, Expressing, MTT Assay, Control